Breaking News Instant updates and real-time market news.

CANF

Can-Fite BioPharma

$2.98

-0.05 (-1.65%)

07:09
06/03/19
06/03
07:09
06/03/19
07:09

Can-Fite says Phase II liver cancer study did not meet primary endpoint

Can-Fite BioPharma announced that data from its recently completed Phase II trial in patients with hepatocellular cancer, the most common form of liver cancer, was presented at the late-breaking abstract session of the 54th Annual Meeting of the American Society of Clinical Oncology. Prof. Salomon M. Stemmer, Principal Investigator of Can-Fite's Phase II trial, delivered the presentation on Sunday June 2, 2019 at the Developmental Immunotherapy and Tumor Immunobiology session. The presentation is entitled: "A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson, an a3 adenosine receptor agonist, as a second-line treatment in patients with Child-Pugh B advanced hepatocellular carcinoma." While the Phase II study did not achieve its primary endpoint of overall survival in the whole population, superiority in overall survival was found in the largest study subpopulation of patients who were classified Child Pugh B7, based on severity of disease compared to the placebo treated group. Median survival in the Namodenoson group was 6.8 months, versus 4.3 months for the placebo group. The "most impressive" finding was that 44% of the patients with Child Pugh B7 treated with Namodenoson were alive at one year compared to 18% in the placebo group. In the overall patient population, among patients who had at least one assessment post baseline, disease control was significant in the Namodenoson group, 26% versus 10% in the control group after four months of treatment, P value 0.013. Among the other positive findings that were presented is the 9% partial response in the Namodenoson treated group vs. 0% in the placebo group. An example of a patient demonstrating an excellent tumor shrinkage was presented. A3AR expression level at baseline was 1.98+/-0.36 in comparison to 1 unit in healthy subjects and was not changed substantially during the treatment period, demonstrating that continuous treatment with Namodenoson does not result in de-sensitization or loss of the target. Consistent with its previously demonstrated favorable safety profile, Namodenoson showed an adverse event profile that was comparable to that of placebo.

CANF Can-Fite BioPharma
$2.98

-0.05 (-1.65%)

06/13/18
HCWC
06/13/18
INITIATION
Target $8
HCWC
Buy
Can-Fite BioPharma assumed with a Buy at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert assumed coverage of Can-Fite BioPharma with a Buy rating and $8 price target. The analyst believes the company's adenosine receptor's differential expression levels make it a good target for drug development in autoimmune disease and cancer.
06/13/18
06/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Liberty Global (LBTYA) initiated with a Sell at Berenberg. 2. Emergent BioSolutions (EBS) initiated with a Buy at Argus. 3. Nine Energy Services (NINE) initiated with a Strong Buy at Raymond James. 4. Can-Fite BioPharma (CANF) assumed with a Buy at H.C. Wainwright. 5. Control4 (CTRL) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/31/18
HCWC
10/31/18
NO CHANGE
HCWC
Buy
H.C. Wainwright 'cautiously optimistic' about Can-Fite after trial results delay
After Can-Fite BioPharma announced earlier today that top line efficacy results are now expected during the first quarter of 2019 in its Phase 2 clinical trial of drug candidate Namodenoson for the treatment of advanced hepatocellular carcinoma due to patient survival, H.C. Wainwright analyst Jason Kolbert said he is "cautiously optimistic" given that he finds it surprising that the trial has gone on this long. His understanding is that a six week or bigger difference between the active and control arms is considered clinically meaningful in this indication, adding that if the data is strong enough the trial is could be used as a registrational study given the unmet medical need. He keeps a Buy rating on Can-Fite shares, which were down 5% in morning trading.
03/27/19
HCWC
03/27/19
NO CHANGE
Target $3
HCWC
Buy
Can-Fite selloff yesterday on trial miss unwarranted, says H.C. Wainwright
H.C. Wainwright analyst Vernon Bernardino recommends Can-Fite BioPharma shares, especially on weakness, based on expectations for positive catalysts with piclidenoson in 2019. The company yesterday announced that its Phase 2 study with namodenoson in hepatocellular carcinoma did not achieve its primary endpoint of overall survival. The analyst, however, did not have this indication in his model and thinks the stock pullback yesterday is unwarranted. He recommends Can-Fite shares based on the potential for second half of 2019 data readouts from Phase 3 studies with its lead candidate piclidenoson in rheumatoid arthritis and psoriasis to be positive. Bernardino reiterates a Buy rating on Can-Fite BioPharma with a $3 price target. The stock closed yesterday down 28%, or 36c, to 93c.

TODAY'S FREE FLY STORIES

TER

Teradyne

$59.96

1.05 (1.78%)

14:35
10/21/19
10/21
14:35
10/21/19
14:35
Options
Teradyne put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 31

    Oct

14:35
10/21/19
10/21
14:35
10/21/19
14:35
General news
Treasury Action: supply kicks off Tuesday with the $40 B 2-year auction »

Treasury Action: supply…

I

Intelsat

$25.44

-1.03 (-3.89%)

14:32
10/21/19
10/21
14:32
10/21/19
14:32
Hot Stocks
Eutelsat tells FCC payment to Treasury shouldn't be over 50%, Bloomberg says »

Eutelsat executives, in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

BA

Boeing

$329.63

-14.46 (-4.20%)

14:27
10/21/19
10/21
14:27
10/21/19
14:27
Periodicals
EASA sees Boeing 737 MAX being cleared in January 'at earliest,' Reuters says »

The head of Europe's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
10/21/19
10/21
14:17
10/21/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
10/21/19
10/21
14:16
10/21/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTON

Peloton

$22.65

-0.79 (-3.37%)

14:08
10/21/19
10/21
14:08
10/21/19
14:08
On The Fly
Peloton's rough ride continues despite Buy ratings from most on Street »

Shares of Peloton (PTON)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERJ

Embraer

$16.89

-0.13 (-0.76%)

14:05
10/21/19
10/21
14:05
10/21/19
14:05
Hot Stocks
Flexjet announces $1.4B jet order from Embraer »

Flexjet announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

HUYA

Huya

$22.02

0.555 (2.59%)

14:05
10/21/19
10/21
14:05
10/21/19
14:05
Options
HUYA call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BB

BlackBerry

$5.21

0.125 (2.46%)

14:04
10/21/19
10/21
14:04
10/21/19
14:04
Hot Stocks
BlackBerry promotes McClurg to CISO, Hummel to CIO »

BlackBerry Limited has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 19

    Nov

BA

Boeing

$330.16

-13.93 (-4.05%)

14:03
10/21/19
10/21
14:03
10/21/19
14:03
Periodicals
Boeing CEO cites 'steady progress' on 737 MAX in internal email, Reuters says »

Boeing CEO Dennis…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BA

Boeing

$330.72

-13.37 (-3.89%)

14:00
10/21/19
10/21
14:00
10/21/19
14:00
Periodicals
EASA sees Boeing 737 MAX being cleared in January 'at earliest,' Reuters says »

The head of Europe's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

TEVA

Teva

$7.75

0.25 (3.33%)

13:58
10/21/19
10/21
13:58
10/21/19
13:58
Hot Stocks
Teva settles Ohio opioid cases, has framework in place to settle remaining cases »

Teva Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 07

    Dec

F

Ford

$9.03

0.035 (0.39%)

13:58
10/21/19
10/21
13:58
10/21/19
13:58
Hot Stocks
Ford to spend more than self-driving commitment of $4B through 2023 »

Jim Farley, Ford's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

TSCO

Tractor Supply

$92.65

-0.71 (-0.76%)

13:55
10/21/19
10/21
13:55
10/21/19
13:55
Options
Tractor Supply put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 13

    Nov

KSU

Kansas City Southern

$146.92

1.54 (1.06%)

13:51
10/21/19
10/21
13:51
10/21/19
13:51
Recommendations
Kansas City Southern analyst commentary  »

Kansas City Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

KGJI

Kingold Jewelry

$0.56

-0.0212 (-3.62%)

13:48
10/21/19
10/21
13:48
10/21/19
13:48
Hot Stocks
Kingold Jewelry announces 1-for-6 reverse split of common stock »

Kingold Jewelry announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKAM

Akamai

$91.72

0.15 (0.16%)

13:35
10/21/19
10/21
13:35
10/21/19
13:35
Hot Stocks
Akamai says peak traffic on Akamai intelligent edge platform exceeds 100 Tbps »

Akamai announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

  • 05

    Nov

  • 06

    Nov

  • 19

    Nov

  • 09

    Dec

VRTX

Vertex

$176.23

-0.01 (-0.01%)

13:29
10/21/19
10/21
13:29
10/21/19
13:29
Hot Stocks
Vertex says Spanish government approves national reimbursement of CF combos »

Vertex Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

STRM

Streamline Health

$1.20

0.02 (1.69%)

, AGO

Assured Guaranty

$47.16

0.28 (0.60%)

13:19
10/21/19
10/21
13:19
10/21/19
13:19
On The Fly
Fly Insider: Streamline, Proofpoint among week's notable insider trades »

Welcome to "Fly Insider,"…

STRM

Streamline Health

$1.20

0.02 (1.69%)

AGO

Assured Guaranty

$47.16

0.28 (0.60%)

TAYD

Taylor Devices

$10.72

0.21 (2.00%)

CMCT

CIM Commercial Trust

$14.70

0.1 (0.68%)

ATNX

Athenex

$9.81

-0.39 (-3.82%)

OKTA

Okta

$101.00

2.32 (2.35%)

LRCX

Lam Research

$239.22

5.56 (2.38%)

FISV

Fiserv

$104.30

-1.41 (-1.33%)

PFPT

Proofpoint

$120.13

0.7 (0.59%)

ANET

Arista Networks

$245.27

5.57 (2.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 31

    Oct

  • 05

    Nov

  • 05

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 08

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 20

    Nov

  • 09

    Dec

  • 12

    Dec

  • 16

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
10/21/19
10/21
13:17
10/21/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
10/21/19
10/21
13:16
10/21/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRM

Iron Mountain

$33.96

0.44 (1.31%)

13:15
10/21/19
10/21
13:15
10/21/19
13:15
Options
Iron Mountain put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 12

    Nov

BA

Boeing

$333.70

-10.39 (-3.02%)

13:05
10/21/19
10/21
13:05
10/21/19
13:05
Periodicals
Boeing CEO cites 'steady progress' on 737 MAX in internal email, Reuters says »

Boeing's CEO said in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

FTCH

Farfetch

$8.18

0.15 (1.87%)

13:05
10/21/19
10/21
13:05
10/21/19
13:05
Options
Farfetch Limited call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.